Alloimmunization is a major complication of blood transfusion which occurs more frequently in patients who are chronically transfused. It causes serologic investigations and makes the selection of compatible blood difficult, expensive and time-consuming. Prompt availability of compatible units for patients with complex alloimmunization requires access to an inventory of extensively typed blood and to a database of rare donors. There are two key factors for rare donor provision. First, the routine programmes of red cell antigen typing in large cohorts of donors. Second, the ability to enrol healthy donors and patients negative for high-prevalence antigens as well as family members. The immunohaematology laboratory is a highly specialized unit in charge of identifying challenging antibodies. It uses multiple methods of analysis and a broad inventory of reagents and cells not easily available. The laboratory also finds compatible blood units for patients with complex alloimmunization and designs appropriate transfusion strategies for these patients often in cooperation with international programmes.
Introduction
Blood group antigens are expressed on proteins, glycoproteins or glycolipids on the outside surface of the red blood cell (RBC) membrane. There are currently 352 blood group antigens recognized by the International Society of Blood Transfusion (ISBT), included in 36 blood group systems, collections, 700 and 901 series (http://www.isbtweb. org/working-parties/red-cell-immunogenetics-and-bloodgroup-terminology/). The consequence of extensive polymorphism in blood groups is an immune response to foreign RBC antigens as a result of transfusion, pregnancy or transplantation. Although blood transfusion is generally very safe, one of the adverse reactions caused by the exposure to allogenic RBCs is the development of RBCs antibodies (alloimmunization). The risk of alloimmunization depends on immunogenicity of the antigen, genetic disparities between blood donor and recipient, genetic or acquired factors, diagnosis, number and frequency of transfusions. The presence of antibodies can cause immediate or delayed transfusion reactions and in pregnancy can result in foetal and neonatal anaemia [1] [2] [3] [4] [5] . Alloimmunization is a significant complication for patients who require multiple or chronic RBC transfusions, as it complicates serologic investigations and makes the selection of compatible blood difficult, expensive and time-consuming. Studies on the frequency of alloimmunization have shown that approximately 2-3% of the transfused patients will form alloantibodies. The frequency is about three times higher in patients previously alloimmunized [6] . Rates can be very high in selected groups of regularly transfused patients such as those suffering from thalassaemia or sickle cell disease (SCD). Among transfused patients with myelodysplastic syndrome or chronic myelomonocytic leukaemia, the prevalence of alloimmunization is 15% and mostly involves the Rh and Kell systems [7] . In thalassaemia and patients with SCD, alloimmunization varies greatly, ranging from 4% to 37% and 7% to 70%, respectively. The rates of alloimmunization depend primarily on the extent of minor RBC antigen matching and exposure frequency [8, 9] . A careful evaluation of the presence of irregular red cell antibodies must be carried out in patients undergoing transfusion therapy, and the provision of compatible blood may become particularly challenging for patients developing alloantibodies to high-prevalence antigens or multiple antibodies to common antigens for which blood is not readily available [10] . Transfusion support of these patients needs cooperation between the Immunohaematology Reference Laboratory (IRL), transfusion specialists, blood bank, clinicians and can involve national and international cooperation.
The Immunohaematology Reference Laboratory (IRL)
The clinical effects of alloimmunization are heightened in complex cases such as those involving antibodies against high-prevalence antigens or combinations of antibodies. On these rare occasions, it becomes essential to turn to an IRL. The availability of a well-developed regional, national or international IRL is extremely beneficial for identification and confirmation of antibody specificity.
The IRL is a highly specialized laboratory that carries out the following functions: (1) might not be available in a timely manner especially when the blood is coming from a foreign blood centre and the IRL must be able to communicate effectively at all times with the clinicians responsible for the patient to reduce risk due to incompatible transfusions and to determine the best course of action for the patient. When units have to be thawed in the blood centre of origin, the short preservation time of thawed RBCs may be a serious problem. Furthermore, one of the major problems encountered is logistic problems in transporting the blood product especially when units are sent from aboard due to import/export procedures. Finally, the lack of experience of many physicians concerning the clinical significance of different alloantibodies, rare blood availability, procedures and time required for their provision may hamper transfusion support of such patients. Seltsam et al. reported a retrospective analysis on 52 hospitalized patients with antibodies to high-prevalence antigens where transfusion support was unsatisfactory in about one-third of the hospitalized patients with antibodies to high-frequency antigens. The lack of compatible RBC units for these patients is a potential hazard that could often be avoided when properly recognized and addressed. If antigen-negative units are not available, autologous donation can be considered or family studies to identify potential blood donors [10] . For the timely provision of antigen-negative and rare blood products, the IRL should have adequate standard operations procedures (SOPs) for antibody identification, management of patients with clinically significant antibodies, thawing and administering of rare units and trained staff to perform antibody investigation and identification.
Rare donor and rare donor programmes
One strategy to find compatible units for subjects with complex red cell immunization is to set up registries and banks of rare donors in order to ensure suitable transfusion support.
As the prevalence of blood group antigens varies among different ethnic groups, the definition of 'rare blood donor' varies from country to country and depends on the ethnicity of the population. D-negative blood has a prevalence of 15% in Caucasian population but less than 1% in Asia. Similarly, Fy (a-) blood has a prevalence of 32% in Caucasian population but less than 4% in Asia. Therefore, if an Asian patient needs Fy (a-) and D-negative blood, the likelihood to find suitable blood will be very challenging. For this reason, there is no complete consensus concerning the definition of rare donor. However, in the vast majority of the countries, an individual is recognized as a rare blood donor when RBCs are negative: (1) for high-prevalence antigens with an occurrence less than 1 in 1000 (but 4 in 1000 in France and 1 in 100 to 1 in 1000 in Japan) (2) for multiple common antigens with an occurrence that varies from 1 in 200 to 1 in 1000 [11] . In most instances, compatible blood is readily available, but an associated challenge is providing especially rare blood in a time-sensitive situation. Indeed, prompt availability of suitable units for patients with complex alloimmunization requires access to an inventory of extensively typed blood as well to a database of rare donors and may involve national or international searches.
There are a number of ways to identify rare blood donors. The key factors are [12, 13] as follows: (1) routinely carry out programmes of typing RBC antigens in large cohorts of donors with automated high-throughput molecular or serological methods. A programme of mass antigen screening should continuously provide information of the phenotypes of the donor population and secure the ability to maintain a stable and sufficient daily inventory of antigennegative RBC units for the more common antibodies. The screening of donors may be done efficiently and cheaply on a large scale for all clinical significant blood groups using high-throughput molecular biology methods followed by serological verification. antigen into autologous or allogenic RBC storage programmes. Patients with a rare blood group are mostly found in routine antibody screening for blood transfusion or antenatal antibody screening. All patients who are eligible at a later date to be allogenic or autologous donors should be encouraged to donate and have their blood frozen for future needs. (5) donor selection from family members, especially siblings, of patients immunized against high-prevalence antigens. In cases of a single antibody to a high-prevalence antigen, approximately one in four siblings will have the same rare blood group. If others antibodies to common antigens are also involved, the chance is lower but higher than in the random population. In numerous countries, one national or a few regional IRLs are responsible for the screening, selection and supply of rare blood. They undertake regular typing of a large number of donors from the area they serve to set up registries of rare donors and banks of frozen blood to ensure suitable transfusion support for the most critical cases. In the majority of cases, regional or national rare donor programmes are able to handle patients with complex alloimmunization even if sometimes additional international help may be required. Therefore, in 1965, an International Rare Donor Panel (IRDP) of blood donors of rare types was established as an ISBT initiative in collaboration with the World Health Organization. The purpose of the panel was to find and facilitate exchange of rare blood units between countries for patients in urgent situations. In 1985, the Working Party on Rare Donors composed of experts in rare donor activities was established. The member countries of ISBT Working Party on Rare Donors support the continued replenishment of rare donors and provision of their units worldwide by continuing to identify and submit donors to the IRDP (http:// www.isbtweb.org/working-parties/rare-donors/). The organization and maintenance of the IRDP are located at the International Blood Group Reference Laboratory (IBGRL) in Bristol [21, 22] . Currently, the IRDP database consists of 8000 donors, and the information is available via Internet. In a recent review, the members of the Working Party have provided a list of the most challenging types to obtain for their country [23] [24] [25] . Rh null type is recognized as the rarest in the world. This indicates that an alloimmunized patient with an Rh null type would be extremely difficult to support even with international cooperation. Other types extremely difficult to find are K o , O h and PP1Pk. The American Rare Donor Program (ARDP) is a joint programme of the American Association of Blood Banks (AABB) and the American Red Cross Blood Service formed in 1998. The databases of both organizations were merged into the ARDP database, REGGI, which includes information on more than 59 000 active rare donors submitted by ARDP members that are AABB-accredited Immunohaematology Reference Laboratories [26] .
Many centres have developed programmes to identify, freeze and store rare blood to be able to meet the needs of the local area for transfusion. Since 1950, cryopreservation has been used in transfusion medicine to preserve RBCs. Two methods have been described, but the highglycerol technique for RBC storage at À80°C is currently predominantly used. Because blood in the liquid state has a short shelf life, a frozen blood inventory is beneficial for very rare blood types that are accessible for at least 10 years and longer. The 10-year outdate is largely applied in different countries throughout the world (e.g. United States, South Africa). In the USA, rare frozen units may be used beyond the expiration date, but only after medical review and approval based on the patient's needs and availability of other rare compatible units. In Europe, the European Guidelines state that storage of frozen RBC units is possible for at least 10 years, but each European country has established own national law. There are several studies that address the quality of cryopreserved RBCs stored in excess of 10 years [27, 28] . Valeri et al. assessed 80 RBC units cryopreserved with glycerol and stored at À80°C for up to 37 years. The data obtained were acceptable by FDA standards. Peyrard et al. reported the French experience where, despite European recommendations, no official mandatory outdate about the validity of rare frozen RBC units exists: 118 rare blood units older than 10 years were transfused between 1994 and 2007, and no transfusion reactions or evidence of haemolysis of thawed RBCs was reported. So, based on this experience and data, it could be safe and efficient to transfuse rare frozen RBC units older than 10 years. The period of validity of rare frozen RBC units should ideally be the same for all rare blood banks throughout the world. The data provided and future data could be used to guide the development of international standards for extending the storage of cryopreserved rare blood by providing quality control of the thawed RBC units. A specific problem for long-term preservation of rare RBC units is testing for mandatory markers for transfusion-transmitted diseases according to the current national regulations. As eligibility requirements for donors change and new infectious tests can be included over the years, it will be important to discuss the best policy to be adopted.
Conclusion
The IRL is responsible for identifying and providing compatible blood for patients with rare blood types and for multiply transfused patients. To achieve this role, the IRL must adopt high-quality standards and have specialized laboratory staff. In addition, a close collaboration between the IRL and clinicians is essential for management of patients who need rare blood units. To find rare donors, in recent years, a variety of algorithms have been used, which include automated serologic testing and molecular typing. The present migration of people throughout the world and mingling of different populations may well result in difficult serologic problems arising. The use of collaboration between regional, national and international IRLs capable of the resolution of very complex serological cases and combined with the availability of with inventories of rare red cells enables patients requiring rare blood types to receive the right blood to the right time.
